clinical trial · NCT01521923
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
UCB Pharma·phase3·completed·n = 359
Rheumatoid ArthritisCertolizumab Pegol + Methotrexate (MTX)Placebo + Methotrexate (MTX)
brief summary
This study is intended to evaluate the efficacy and safety of Certolizumab Pegol (CZP) in combination with Methotrexate (MTX) for sustaining clinical response achieved in study RA0055 Period 1 \[NCT01519791\]. Subjects entering this study RA0055 Period 2 achieved sustained Low Disease Activity at Week 52 in study RA0055 Period 1.
started
Jan 1, 2012
primary completion
Jul 1, 2015
completion
Sep 1, 2015
last updated
Aug 25, 2026
official title
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate for Inducing and Sustaining Clinical Response in the Treatment of DMARD-Naïve Adults With Early Active Rheumatoid Arthritis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol